Replimune Group (NASDAQ:REPL) Shares Up 5.3% – Still a Buy?

Replimune Group, Inc. (NASDAQ:REPL) shares shot up 5.3% during trading on Monday. The stock traded as high as $12.14 and last traded at $12.0640. 201,064 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 4,305,646 shares. The stock had previously closed at $11.46.

Wall Street Analysts Forecast Growth

REPL has been the subject of several analyst reports. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective on the stock in a research note on Tuesday, June 30th. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price on the stock in a research note on Friday, August 7th. Weiss Ratings cut Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. increased their price target on shares of Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $12.00.

Replimune Group Trading Up 8.1%

The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. The stock’s fifty day moving average price is $13.53 and its 200 day moving average price is $9.88. The stock has a market capitalization of $1.16 billion, a P/E ratio of -3.92 and a beta of 0.93.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). Research analysts forecast that Replimune Group, Inc. will post -2.82 earnings per share for the current year.

Insider Activity

In related news, CFO Emily Hill sold 9,256 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $14.28, for a total value of $132,175.68. Following the transaction, the chief financial officer directly owned 215,852 shares of the company’s stock, valued at $3,082,366.56. This trade represents a 4.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $98,987.04. Following the sale, the chief accounting officer owned 99,425 shares of the company’s stock, valued at approximately $1,289,542.25. This represents a 7.13% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 79,124 shares of company stock worth $1,038,364. Company insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of REPL. BlackRock Inc. acquired a new stake in Replimune Group in the second quarter worth about $99,171,000. Opaleye Management Inc. purchased a new position in shares of Replimune Group in the second quarter worth approximately $15,332,000. EcoR1 Capital LLC acquired a new stake in shares of Replimune Group in the first quarter worth $7,650,000. ADAR1 Capital Management LLC purchased a new position in Replimune Group during the 2nd quarter valued at about $7,260,000. Finally, Jefferies Financial Group Inc. purchased a new position in Replimune Group during the second quarter valued at approximately $5,485,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.